Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Numakura, Kazuyuki, Sekine, Yuya, Hatakeyama, Shingo, Muto, Yumina, Sobu, Ryuta, Kobayashi, Mizuki, Sasagawa, Hajime, Kashima, Soki, Yamamto, Ryohei, Nara, Taketoshi, Akashi, Hideo, Tabata, Ryuji, Sato, Satoshi, Saito, Mitsuru, Narita, Shintaro, Ohyama, Chikara, Habuchi, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501267/
https://www.ncbi.nlm.nih.gov/pubmed/37403728
http://dx.doi.org/10.1002/cam4.6306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501267/
https://www.ncbi.nlm.nih.gov/pubmed/37403728
http://dx.doi.org/10.1002/cam4.6306

Ejemplares similares